Home/Filings/4/0001104659-20-083784
4//SEC Filing

Malin Life Sciences Holdings Ltd 4

Accession 0001104659-20-083784

CIK 0001661460other

Filed

Jul 14, 8:00 PM ET

Accepted

Jul 15, 5:00 PM ET

Size

29.4 KB

Accession

0001104659-20-083784

Insider Transaction Report

Form 4
Period: 2020-07-14
Transactions
  • Conversion

    Common Stock

    2020-07-14+1,168,9858,182,903 total
  • Conversion

    Series A Preferred Stock

    2020-07-148,746,3560 total
    Common Stock (7,013,918 underlying)
  • Conversion

    Series A-1 Preferred Stock

    2020-07-141,457,7250 total
    Common Stock (1,168,985 underlying)
  • Conversion

    Series C Preferred Stock

    2020-07-14392,9270 total
    Common Stock (315,098 underlying)
  • Conversion

    Common Stock

    2020-07-14+315,0989,188,125 total
  • Conversion

    Series B Preferred Stock

    2020-07-14860,5850 total
    Common Stock (690,124 underlying)
  • Conversion

    Common Stock

    2020-07-14+7,013,9187,013,918 total
  • Conversion

    Common Stock

    2020-07-14+690,1248,873,027 total
Transactions
  • Conversion

    Series A-1 Preferred Stock

    2020-07-141,457,7250 total
    Common Stock (1,168,985 underlying)
  • Conversion

    Series B Preferred Stock

    2020-07-14860,5850 total
    Common Stock (690,124 underlying)
  • Conversion

    Series C Preferred Stock

    2020-07-14392,9270 total
    Common Stock (315,098 underlying)
  • Conversion

    Common Stock

    2020-07-14+7,013,9187,013,918 total
  • Conversion

    Common Stock

    2020-07-14+690,1248,873,027 total
  • Conversion

    Series A Preferred Stock

    2020-07-148,746,3560 total
    Common Stock (7,013,918 underlying)
  • Conversion

    Common Stock

    2020-07-14+1,168,9858,182,903 total
  • Conversion

    Common Stock

    2020-07-14+315,0989,188,125 total
Footnotes (2)
  • [F1]All shares of preferred stock, $0.0001 par value per share, of the Issuer, (i) had no expiration date and (ii) automatically converted into the Issuer's common stock, $0.0001 par value per share, on a 1-for-0.8019246 basis immediately prior to the closing of the Issuer's initial public offering.
  • [F2]Malin Life Sciences Holdings Ltd, the record holder of the shares, is a wholly owned subsidiary of Malin Corporation plc. Malin Corporation plc may be deemed to beneficially own the shares and may be deemed to share voting and dispositive power over these shares.

Issuer

Poseida Therapeutics, Inc.

CIK 0001661460

Entity typeother
IncorporatedIreland

Related Parties

1
  • filerCIK 0001685138

Filing Metadata

Form type
4
Filed
Jul 14, 8:00 PM ET
Accepted
Jul 15, 5:00 PM ET
Size
29.4 KB